Pfizer, Inc (NYSE: PFE), New York, has notified the European Medicines Agency (EMA) of its decision to withdraw an application to extend the therapeutic indication… Read More »Pfizer withdraws application for an extension of the indication for Macugen
Regeneron Pharmaceuticals (NASDAQ:REGN), Tarrytown, New York, will undergo an FDA priority review of its VEGF Trap Eye (recently renamed “Eylea aflibercept”) on August 20th, the… Read More »Regeneron Pharmaceutical’s pricing strategy may be key to success
In a collaboration with the University of Birmingham, Quark Pharmaceuticals, a Californian based biotech company with research facilities at the Weismann Science Park in Israel,… Read More »Quark Pharmaceuticals Inc. and the University of Birmingham publishes data on anti-apoptotic result
Regeneron Pharmaceuticals & Bayer Healthcare have announced the submission of a marketing authorisation application (MAA) for VEGF Trap Eye for the treatment of neovascular age… Read More »Regeneron & Bayer file marketing authorisation application for VEGF Trap Eye
Lpath, Inc, a San Diego based therapeutic antibody company quoted on the US OTCBB (LPTN) has announced the initiation of enrolment for its anti-angiogenic antibody… Read More »Lpath Inc initiates Phase 1b/2a trial for iSONEP in retinal detachment and vasculopathy secondary to
Quark Pharmaceuticals, a Californian based RNAi specialised biotech company, has announced changes to a Pfizer collaborative research agreement following receipt of results from a randomized… Read More »Quark announces a revision to an siRNA Pfizer agreement on diabetic macular edema
Alexion Pharmaceuticals has announced an all stock purchase of Taligen Therapeutics, a privately held company based in Cambridge, Massachusetts. The all cash upfront deal for… Read More »Alexion Pharmaceuticals closes a $111 million cash deal for Taligen assets
Results of a Phase 3 study in CRVO and a Phase 2 study in DME have provided a positive outcome for Regeneron’s VEGF Trap-Eye experimental… Read More »Regeneron & Bayer announce clinical results in CRVO & DME with VEGF Trap-Eye
QLT Inc., a Canadian based biotechnology company, has announced that its oral synthetic retinoid product for the treatment of retinitis pigmentosa has been granted orphan… Read More »QLT obtains orphan drug designation for retinitis pigmentosa treatment
December 1st- EURETINA have launched an exciting new initiative to support innovation across Europe in the development of new technologies in the field of retinal… Read More »EURETINA launches new Innovation Awards for 2011